☆ 4.6 Article

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes

JOURNAL OF INFECTION AND PUBLIC HEALTH (2021)

Related references

Note: Only part of the references are listed.

Letter Medicine, General & Internal

Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study

J. Eimer et al.

JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Jesus Rodriguez-Bano et al.

Summary: This study suggests that tocilizumab may help reduce the risk of intubation or death in COVID-19 patients with a hyperinflammatory state. Corticosteroid treatment is less effective than tocilizumab, with combination therapy falling in between.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Infectious Diseases

Treating COVID-19: are we missing out the window of opportunity?

Jeremiah Sundararaj Stanleyraj et al.

Summary: Severe COVID-19 is a biphasic illness characterized by an initial viral replication phase followed by a cascade of inflammatory events. The severity of the disease is primarily determined by the inflammatory cascade rather than viral replication. Therefore, timing is crucial in administering the right antiviral or immunomodulatory therapy during different stages of the disease.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Add to Collection

Review Virology

Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis

Muhammad Aziz et al.

Summary: The efficacy of tocilizumab in severe COVID-19 patients appears to reduce mortality and the need for mechanical ventilation. Further randomized controlled trials are required to confirm these findings.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Shruti Gupta et al.

Summary: A multicenter cohort study found that early treatment with tocilizumab may reduce mortality among critically ill patients with COVID-19. Further research from randomized clinical trials is needed to confirm these findings.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial

Carlo Salvarani et al.

Summary: This study evaluated the use of tocilizumab in hospitalized COVID-19 pneumonia patients and found no significant benefit compared to standard care. Further randomized clinical trials with blinded, placebo-controlled methods are needed to confirm these results and explore potential applications of tocilizumab in different stages of the disease.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia

Jonathan B. Parr

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Review Infectious Diseases

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis

Imad M. Tleyjeh et al.

Summary: This study reviewed the efficacy of the IL-6 receptor antagonist tocilizumab in COVID-19 patients. The results showed that tocilizumab can reduce the risk of mechanical ventilation, but its impact on short-term mortality remains inconclusive. Additionally, the use of tocilizumab does not increase the risk of infections or adverse events.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

COVID-19 and the Heart

Akbarshakh Akhmerov et al.

CIRCULATION RESEARCH (2020)

Add to Collection

Review Rheumatology

Treatment algorithm for COVID-19: a multidisciplinary point of view

Felice Galluccio et al.

CLINICAL RHEUMATOLOGY (2020)

Add to Collection

Letter Medicine, General & Internal

Postmortem Examination of Patients With COVID-19

Tina Schaller et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Allergy

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Xiaochen Li et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Clinical and immunological features of severe and moderate coronavirus disease 2019

Guang Chen et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

COVID-19 illness in native and immunosuppressed states: A clinical?therapeutic staging proposal

Hasan K. Siddiqi et al.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2020)

Add to Collection

Article Virology

Tocilizumab for the treatment of severe coronavirus disease 2019

Rand Alattar et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

Chaomin Wu et al.

JAMA INTERNAL MEDICINE (2020)

Add to Collection

Article Infectious Diseases

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

T. Klopfenstein et al.

MEDECINE ET MALADIES INFECTIEUSES (2020)

Add to Collection

Article Medicine, General & Internal

Covid-19 in Critically Ill Patients in the Seattle Region - Case Series

Pavan K. Bhatraju et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Rheumatology

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study

Sofia Ramiro et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

Add to Collection

Review Infectious Diseases

Tocilizumab for severe COVID-19: a systematic review and meta-analysis

Shao-Huan Lan et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)

Add to Collection

Article Infectious Diseases

Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients

Timothee Klopfenstein et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Review Virology

Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review

Saeed K. Alzghari et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia

Malgorzata Mikulska et al.

PLOS ONE (2020)

Add to Collection

Article Hematology

Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children

Caroline Diorio et al.

BLOOD ADVANCES (2020)

Add to Collection

Review Medicine, General & Internal

Cytokine Storm

David C. Fajgenbaum et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Rheumatology

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Giovanni Guaraldi et al.

LANCET RHEUMATOLOGY (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.